时珍国医国药2025，Vol.36Issue(23)：4436-4443,8.DOI:10.70976/j.1008-0805.SZGYGY-2025-2305
基于RhoA/ROCK1通路的肾衰泄浊汤抗CKD伴AS的机制研究
Mechanism of Shenshuai Xiezhuo Decoction(肾衰泄浊汤)against CKD complicated with AS based on the RhoA/ROCK1 pathway
摘要
Abstract
Objective To investigate the mechanism by which Shenshuai Xiezhuo Decoction(肾衰泄浊汤,SSXZD)inhibits chronic kidney disease complicated with atherosclerosis(CKD AS)through regulating the RhoA/ROCK1 pathway.Methods Sixty SD rats were randomly divided into the sham-operated group,model group,losartan group(20 mg/kg/d),and the SSXZD low/medium/high-dose groups(6.0,12.0,24.0 g/kg/d).The CKD AS model was established by 5/6 nephrectomy combined with high-fat diet feeding,fol‐lowed by 8 weeks of intervention.Serum levels of Serum Creatinine(SCr),Urea(UREA),Total Cholesterol(TC)and Triglycerides(TG)were measured.Pathological changes in the aorta and kidney were observed using HE and Masson staining.RT-PCR was used to measure mRNA levels of RhoA,ROCK1,and NF-κB in aortic tissues.Western blot(WB)and immunohistochemistry(IHC)were used to detect protein expression of RhoA,ROCK1 and NF-κB in aortic tissues.Results Compared with the sham-operated group,the model group showed significantly elevated levels of SCr,UREA,TC,and TG(P<0.01),which were reduced in all treatment groups(P<0.01).The model group exhibited lipid deposition in the aortic intima,destruction of the medial structure,and renal collagen fiber proliferation.Pathological damage was significantly alleviated in the medium/high-dose groups of SSXZD.The mRNA and protein expression levels of RhoA,ROCK1,and NF-κB were upregulated in the model group(P<0.01).SSXZD dose-dependently sup‐pressed their expression.Conclusion SSXZD can alleviate arterial inflammation,protect vascular endothelial cells,and thereby inhibit the occurrence of AS in CKD AS,which may be associated with suppression of RhoA/ROCK1 pathway activation.关键词
肾衰泄浊汤/慢性肾脏病/动脉粥样硬化/RhoA/ROCK1Key words
Shenshuai Xiezhuo Decoction(肾衰泄浊汤)/Chronic kidney disease/Atherosclerosis/RhoA/ROCK1分类
医药卫生引用本文复制引用
卢姚宏,刘庚鑫,袁文萋,张格第,周海东,晏子友..基于RhoA/ROCK1通路的肾衰泄浊汤抗CKD伴AS的机制研究[J].时珍国医国药,2025,36(23):4436-4443,8.基金项目
国家自然科学基金(82260908 （）
81960843) （）
江西省大学生创新创业训练计划项目(S202510412042) （S202510412042）
